FR2481602A1 - Composition et procede pour le traitement du cancer - Google Patents
Composition et procede pour le traitement du cancer Download PDFInfo
- Publication number
- FR2481602A1 FR2481602A1 FR8108520A FR8108520A FR2481602A1 FR 2481602 A1 FR2481602 A1 FR 2481602A1 FR 8108520 A FR8108520 A FR 8108520A FR 8108520 A FR8108520 A FR 8108520A FR 2481602 A1 FR2481602 A1 FR 2481602A1
- Authority
- FR
- France
- Prior art keywords
- brain tissue
- tissue
- mammalian
- suspension
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 48
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 201000011510 cancer Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 18
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 24
- 108010034634 Repressor Proteins Proteins 0.000 claims abstract description 18
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108010074605 gamma-Globulins Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 210000000944 nerve tissue Anatomy 0.000 claims description 3
- 210000005171 mammalian brain Anatomy 0.000 claims 9
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 51
- 102000009661 Repressor Proteins Human genes 0.000 description 13
- 241000699800 Cricetinae Species 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 108700005075 Regulator Genes Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14541980A | 1980-05-01 | 1980-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2481602A1 true FR2481602A1 (fr) | 1981-11-06 |
| FR2481602B1 FR2481602B1 (OSRAM) | 1984-06-01 |
Family
ID=22513026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8108520A Granted FR2481602A1 (fr) | 1980-05-01 | 1981-04-29 | Composition et procede pour le traitement du cancer |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5874615A (OSRAM) |
| CA (1) | CA1175741A (OSRAM) |
| CH (1) | CH655659B (OSRAM) |
| DE (1) | DE3116733A1 (OSRAM) |
| ES (1) | ES501835A0 (OSRAM) |
| FR (1) | FR2481602A1 (OSRAM) |
| GB (1) | GB2075988B (OSRAM) |
| MX (1) | MX6826E (OSRAM) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2717227A (en) * | 1954-12-22 | 1955-09-06 | Helen L Dawson | Composition containing nerve tissue extract and process of producing such extract |
| GB866509A (en) * | 1956-05-22 | 1961-04-26 | Univ Tulane | Therapeutic agent prepared from brain tissues and the preparation of such agent |
-
1981
- 1981-04-28 DE DE19813116733 patent/DE3116733A1/de not_active Withdrawn
- 1981-04-29 FR FR8108520A patent/FR2481602A1/fr active Granted
- 1981-04-30 GB GB8113341A patent/GB2075988B/en not_active Expired
- 1981-04-30 MX MX819434U patent/MX6826E/es unknown
- 1981-04-30 ES ES501835A patent/ES501835A0/es active Granted
- 1981-05-01 CH CH286381A patent/CH655659B/de not_active IP Right Cessation
- 1981-10-22 CA CA000388472A patent/CA1175741A/en not_active Expired
- 1981-10-30 JP JP56174406A patent/JPS5874615A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2717227A (en) * | 1954-12-22 | 1955-09-06 | Helen L Dawson | Composition containing nerve tissue extract and process of producing such extract |
| GB866509A (en) * | 1956-05-22 | 1961-04-26 | Univ Tulane | Therapeutic agent prepared from brain tissues and the preparation of such agent |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8300477A1 (es) | 1982-11-01 |
| ES501835A0 (es) | 1982-11-01 |
| JPS5874615A (ja) | 1983-05-06 |
| GB2075988B (en) | 1983-09-01 |
| MX6826E (es) | 1986-08-08 |
| GB2075988A (en) | 1981-11-25 |
| CA1175741A (en) | 1984-10-09 |
| DE3116733A1 (de) | 1982-04-01 |
| CH655659B (OSRAM) | 1986-05-15 |
| FR2481602B1 (OSRAM) | 1984-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5547964B2 (ja) | 生理活性物質を定着および発現させる方法 | |
| FR2488803A1 (fr) | Procede pour la production d'erythropoietine humaine | |
| CA2184841C (fr) | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) | |
| EP0775213B1 (fr) | Adenovirus comprenant un gene codant pour la glutathion peroxydase | |
| Khavinson et al. | Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa | |
| KR20240099216A (ko) | 슈반 세포로의 표적화 전달을 위한 설계자 세포외 소낭 | |
| CN112156104B (zh) | 一种治疗抑郁症的药物 | |
| FR2481602A1 (fr) | Composition et procede pour le traitement du cancer | |
| JPWO2021136263A5 (OSRAM) | ||
| JPWO2017183665A1 (ja) | 制御性ｔ細胞の活性化剤及びその使用 | |
| JP5916051B2 (ja) | 抗炎症剤および抗炎症剤の製造方法 | |
| CA2251009A1 (fr) | Medicament optimisant la viscosite des mucus et stimulant le fonctionnement de l'intestin | |
| FR2717495A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| KR20130116374A (ko) | 예방적 또는 치료적 형태로 투여된 α-ＭＳＨ를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도 | |
| Schenk et al. | Gene therapy: future therapy for erectile dysfunction | |
| US4559228A (en) | Composition and method for the treatment of cancer | |
| KR20200140794A (ko) | 방법 | |
| JP4533144B2 (ja) | 聴覚機能障害用医薬 | |
| US4728511A (en) | Composition and method for the treatment of cancer | |
| RU2058788C1 (ru) | Способ получения препарата инсулина для перорального применения | |
| FR2717496A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| RU2442584C2 (ru) | ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ | |
| RU2230559C1 (ru) | Способ стимулирования колониеобразования кроветворных клеток-предшественников в селезенке при облучении животных | |
| RU2377995C1 (ru) | Способ лечения больных диспепсией новорожденных телят с коррекцией патологической активации тромбоцитов | |
| TW202342761A (zh) | 利用奈米膠囊藥物傳送系統且用於控制血糖水平的組成及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |